The effects of short-term omission of daily medication on the pathophysiology of heart failure by Clark, Andrew L.. et al.
European Journal of Heart Failure (2017)
doi:10.1002/ejhf.748
The effects of short-term omission of daily
medication on the pathophysiology of heart
failure
Silviu Dovancescu1,2,4†*, Pierpaolo Pellicori1†, Thato Mabote1, Azam Torabi1,
Andrew L. Clark1, and John G.F. Cleland1,3*
1Department of Cardiology, Hull York Medical School, Hull and East Yorkshire Medical Research and Teaching Centre, Castle Hill Hospital, Cottingham, Kingston upon Hull, UK;
2Philips Research, Eindhoven, The Netherlands; 3National Heart & Lung Institute and National Institute of Health Research, Cardiovascular Biomedical Research Unit, Royal
Brompton & Harefield Hospitals, Imperial College, London, UK; and 4Department of Electrical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands
Received 10 June 2016; revised 14 December 2016; accepted 15 December 2016
Aims Pharmacological therapies for heart failure (HF) aim to improve congestion, symptoms, and prognosis. Failing to take
medication is a potential cause of worsening HF. Characterizing the effects of short-term medication omission could
inform the development of better technologies and strategies to detect and interpret the reasons for worsening
HF. We examined the effect of planned HF medication omission for 48 h on weight, echocardiograms, transthoracic
bio-impedance, and plasma concentrations of NT-proBNP.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
Outpatients with stable HF and an LVEF<45%were assigned to take or omit their HF medication for 48 h in a random-
ized, crossover trial. Twenty patients (16 men, LVEF 32± 9%, median NT-proBNP 962 ng/L) were included. Compared
with regular medication, omission led to an increase in NT-proBNP by 99% (from 962 to 1883 ng/L, P< 0.001), sys-
tolic blood pressure by 16% (from 131 to 152 mmHg, P< 0.001), and left atrial volume by 21% (from 69 to 80 mL,
P= 0.001), and reductions in transthoracic bio-impedance by 10% (from 33 to 30Σ, P= 0.001) and serum creatinine
by 8% (from 135 to 118 μmol/L, P= 0.012). No significant changes in body weight, heart rate, or LVEF were observed.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusions The characteristic pattern of response to short-term medication omission is of increasing congestion but, in contrast
to the pattern reported for disease progression, with a rise in blood pressure and improved renal function. In stable
HF, weight is not a sensitive marker of short-term diuretic omission.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Keywords Heart failure • Medication omission • Congestion • Cardiac ultrasound • Telemonitoring •
Transthoracic bio-impedance
Introduction
For patients with heart failure (HF), worsening congestion is a com-
mon reason for hospitalizations that might be avoided if the causes
can be identified and treated. Up to one in four people in the gen-
eral population do not take their medication as prescribed,1 while
studies of patients with HF report rates of medication adherence
ranging from 10% to 98%, depending on the definition applied and
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.. the instrument used.2,3 Low adherence to medications may lead to
worsening HF and disease progression, resulting in hospital admis-
sion, increased healthcare costs, and death.3–5 Several methods
have been developed to assess adherence to medication.6 Although
measurement of the blood level of a medicine is a robust and objec-
tive method, it is not currently practical for routine clinical use.3 On
the other hand, indirect methods of adherence (patient question-
naires, self-reports, pill counts, electronic medication monitors,
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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and patient diaries) are often subjective and may be inaccurate.
The aim of this study was to investigate changes in cardiovascu-
lar and renal function following the omission of treatments for HF
for 48 h, in order to provide a clinical model for the study of new
technologies and strategies for the detection and management of
congestion.
Methods
Study population
Outpatients on stable, guideline-indicated therapy for HF, including a
loop diuretic (≥40mg/day of furosemide or ≥1mg/day of bumetanide),
in sinus rhythm with an LVEF <45% on echocardiography and a plasma
concentration of NT-proBNP >200 ng/L were enrolled. Patients with
breathlessness or chest pain at rest or on minimal exertion and
those with implanted pacemakers or defibrillators (that might be
incompatible with the bio-impedance technology) or severe valve
disease were not eligible for the study.
Study design
The HeartCycle Heart Failure Trials Programme of the European
Commission was an observational trial with randomized components
investigating the ability of next-generation home telemonitoring (HTM)
to improve the management of patients with HF. One of its aims was to
investigate how HTMmight be used to improve medication adherence.
Patients were requested to attend on two occasions, on a similar
diet for the 3 days prior to each visit. No other specific dietary restric-
tion was imposed. Each patient was asked to take their medication
as usual prior to one visit (medication taken) and to omit their HF
medications (diuretic, ACE inhibitors, beta-blockers, and aldosterone
antagonists) for 48 h prior to the other (medication omitted). The
visits were scheduled ∼1week apart. The order of the visits was ran-
domized. Patients were phoned the day before the study to ensure
that omission of therapy had not caused any problems. Patients were
advised to contact the research staff and/or take their medication as
usual if they felt any worsening of their condition or gained >2 kg
(4.5 lb).
The study was conducted in accordance with guidelines for clinical
trials and the Declaration of Helsinki. The protocol was approved by all
relevant ethics committees and the hospital research and development
department. Patients provided written informed consent.
Data collection
Conventional telemonitoring measurements
and biochemical data
After voiding urine, patients were weighed (Tanita MC 180MAClass III)
while wearing a light gown. Blood pressure and heart rate were mea-
sured with an automated sphygmomanometer (Microlife AG, Switzer-
land). Blood samples were collected for haematology and biochemistry
profiles including the assessment of plasma NT-proBNP.
Bio-impedance measurements
Whole-body bio-impedance was measured in parallel to body weight
with a commercial body composition analyser (Tanita MC 180MA
Class III) which uses the palms and soles of the subject as electrical ..
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.. contact areas. The device applies predictive modelling to estimate
body composition including total body water from bio-impedance data
measured at four frequencies (5, 50, 250, and 500 kHz) and subject
characteristics, e.g. sex, age, weight, and height.
Transthoracic bio-impedance was measured with a wear-
able bio-impedance monitor (BIM) designed to enable patient
self-assessment (Figure 1). The BIM is an investigational device which
includes an electronic module and an adjustable vest with four
textile electrode pads arranged pair-wise on either side of the rib
cage, at the base of the lungs. The BIM measures bio-impedance at
16 different frequencies distributed logarithmically from 10 kHz to
1MHz. The multifrequency BIM data are used to fit the Cole–Cole
model (Z = R∞ −
R∞−RE
1+
(
j f
fc
)𝛼 ),7,8 which provides information about tissue
characteristics. The model parameters reflect extracellular fluid (RE),
intracellular fluid (R∞), tissue relaxation (fc), and tissue heterogeneity
(𝛼). Intrathoracic fluid accumulation due to worsening HF directly
affects the value of RE, which should decrease.
9,10 BIM measurements
were determined over 3min in the sitting position.
Echocardiographic measurements
Echocardiography was performed by an experienced operator using a
Vivid Nine (GE Healthcare, UK) system operating at 3.4MHz. Doppler
tracings and two-dimensional images were obtained from parasternal
long- and short-axis, apical, and subcostal views. Echocardiograms were
stored and retrospectively reviewed using an EchoPAC station (GE
Healthcare, UK) by a single operator (P.P.) blinded to randomization.
The LVEF was measured using Simpson’s biplane method. Left atrial
(LA) maximum, the frame just before mitral valve opening, and LAmini-
mum, the frame just after mitral valve closure, volumes were measured
in four-chamber view. The LA endocardial border was traced manually.
The anterior border was at the mitral annular plane and the posterior
border at the ostia of the pulmonary veins. The LA emptying func-
tion (LAEF) was measured using the formula: LAVmax – LAVmin/LAVmax.
Peak early velocity (e’) was measured by using tissue Doppler imaging
at the lateral (e’lat) and septal (e’sep) border of the mitral valve annu-
lus. Right ventricular (RV) systolic function was assessed using tricuspid
annular plane systolic excursion (TAPSE).With the patient in the supine
position, the maximum inferior vena cava (IVC) diameter during the
respiratory cycle was measured ∼3 cm before it merged with the right
atrium.
Data analysis and statistics
Categorical data are presented as percentages; normally distributed
continuous data as mean± standard deviation (SD), and non-normally
distributed variables as median and interquartile range. Effects of
medication omission were studied in the overall study population
and in subgroups above and below the median NT-proBNP value.
Relative changes in measures between the visit medication taken
and medication omitted were determined using the formula: Omit-
ted – Taken/Taken. The statistical significance of relative and absolute
changes was assessed using the t-test for normally distributed variables
and Wilcoxon signed rank test otherwise. A P-value <0.05 was con-
sidered statistically significant.
Results
Twenty patients (80% men, mean LVEF 32± 9%, median
NT-proBNP 962 ng/L) were enrolled in the study. Most patients
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Bio-impedance monitor consisting of an adjustable vest with integrated textile electrodes and a slim electronics case.
had mild symptoms (16 in NYHA class II). Patient character-
istics and treatment at baseline are presented in Table 1. All
patients were treated with loop diuretics and beta-blockers,
mainly carvedilol, 18 received either an ACE inhibitor or ARB,
but only 7 (35%) received a mineralocorticoid receptor antag-
onist, although this was consistent with guidelines for patients
with predominantly NYHA class II HF at the time the study was
conducted.
Measurements made during visits with medication taken or
omitted, and the relative changes in each variable are listed in
Table 2, for the overall study group and for patients above and
below the median plasma NT-proBNP. With omission of HF
therapies for 48 h, six patients (30%) reported an increase in
exertional breathlessness with a deterioration in NYHA class by
one rank. Omission of medications was associated with an increase
in systolic blood pressure (from 131 to 152mmHg, P< 0.001)
and plasma NT-proBNP, which almost doubled (from 962 to
1883 ng/L, P< 0.001), and a fall in serum creatinine (from 135
to 118 μmol/L, P= 0.012). Weight, despite omission of diuretics,
and heart rate, despite omission of beta-blockers, did not change.
Amongst echocardiographic measurements, LV and LA volumes
and IVC diameter increased [LV end-diastolic volume (LVEDV),
+11%, P= 0.008; LAVmax, +21%, P< 0.001; IVC diameter, +18%,
P= 0.004]. The transmitral peak E velocity increased (E, +23%,
P= 0.001), indicating a reduction in LAEF. However, LVEF and
E/e’ did not change significantly. Transthoracic BIM decreased (RE,
−10%, P= 0.001), as did total body impedance (Z, −5%, P< 0.001).
Changes in renal function [estimated glomerular filtration rate
(eGFR), +12%, P= 0.015) were mostly driven by improvements
in the subgroup with lower NT-proBNP, while the behaviour
of other measurements was similar regardless of NT-proBNP
subgroup. .
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Table 1 Demographic, clinical, and pharmacological
treatment data for the study population
Characteristics Total cohort (n= 20)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age, years 71 (62, 77)
Women 4 (20)
Aetiology
Ischaemic heart disease 16 (80)
Height, cm 167 (161, 170)
Weight, kg 75 (68, 91)
BMI, kg/m2 28 (24, 32)
NYHA class
I 4 (20)
II 16 (80)
Co-morbidities
Hypertension 13 (65)
Diabetes mellitus 5 (25)
Sinus rhythm 20 (100)
LVEF, % 35 (27, 39)
Treatments
ACE inhibitors or ARBs 18 (90)
Beta-blockers 20 (100)
Loop diuretics 20 (100)
MRA 7 (35)
Digoxin 1 (5)
Data are expressed as median (interquartile range) or absolute number (%).
BMI, body mass index; MRA, mineralocorticoid receptor antagonist.
Discussion
This study shows that withholding medication for 48 h, including
loop diuretics, results in increases in several measures of conges-
tion including a rise in plasma NT-proBNP, increases in atrial and
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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ventricular volumes, and a reduction in transthoracic BIM and, for
some patients, a deterioration in NYHA functional class. Weight, a
commonly used measure of fluid retention and congestion, did not
change significantly. In patients with worsening congestion due to
disease progression, a decline in blood pressure and renal function
would be expected. In contrast, we observed a substantial increase
in systolic blood pressure and improvement in renal function. Thus,
the clinical profiles of congestion due to medication omission and
disease progression appear to differ.
Early identification of congestion, its likely cause, and appropriate
intervention might decrease the need for admission.11 Increases in
heart rate, and changes in heart rhythm and temperature might
be useful in the diagnosis of alternative reasons for worsening
congestion such as arrhythmias or infection. However, medication
non-adherence may be a common problem among patients with
HF; either because they are told to stop (i.e. the patient is
told to withhold medication prior to a procedure), intentional
(i.e. a patient chooses not to take some or several medications
after weighing the risk and benefits against adverse effects, such
as the frequent need to urinate), or unintentional, because the
patient is careless or forgetful about prescribed therapy.3 This
analysis suggests that short-term omission of HF medications does
not cause marked deterioration in symptoms in patients with
mild to moderate HF, although the study is too small to assess
safety fully. However, an increase in congestion was observed and
extension of the period of omission would most probably lead to
overt deterioration in symptoms and signs. Reports from studies
that pre-date modern diagnostic standards indicated that a large
proportion of patients with HF could stop their diuretic indefinitely,
but this may be because these patients did not have, or had only
mild, HF.12–14
Our study shows that withholding HF medicines for 48 h is
associated with an increase in LA volumes and worsening atrial
contraction. The increase in LA volume was mirrored by an
increase in IVC diameter, suggesting a concordant rise in both
right and LA pressure. LV volumes changed less than LA volumes
perhaps because volume measures are less accurate for the ven-
tricle compared with the atrium or because the LV wall thickness
is greater and therefore less likely to be deformed by modest,
short-term increases in pressure. A measure thought to reflect
LA pressure, E/e’, did not change significantly despite a substantial
and consistent increase in E-wave velocity. We did not measure
atrial pressures directly and therefore can only speculate about the
accuracy of E/e’ as a measure of atrial pressure or diastolic dys-
function. Unfortunately, a large proportion of patients did not have
enough tricuspid regurgitation to measure changes in pulmonary
artery pressure that would be expected to accompany congestion.
Our results show that renal function improved after medication
omission. ACE inhibitors, ARBs, beta-blockers, mineralocorticoid
receptor antagonists, and diuretics all conspire to reduce the GFR
and do so either by reducing net arterio-venous renal perfusion
pressure or by complex effects on intraglomerular haemodynam-
ics; therefore, this result is not surprising.15 It is remarkable that so
many agents that improve prognosis cause renal function to decline;
renal dysfunction may also limit their use.16 Interestingly, it was only
patients with lower NT-proBNP whose renal function appeared to ..
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.. benefit from medication omission, suggesting that these patients
might be relatively dehydrated and that more aggressive diuresis,
in an attempt to reduce NT-proBNP further, might have adverse
consequences in such patients.
Increased pressures and wall stress will increase secretion of
natriuretic peptides, leading to a rise in plasma NT-proBNP despite
improved renal function and therefore presumably increased
renal clearance of NT-proBNP. Natriuretic peptides are a natural
defence against congestion, which is useful diagnostically; they are
also powerful markers of prognosis.17–19 Plasma concentrations
of NT-proBNP almost doubled after interrupting treatment for
48 h before any obvious change in weight and before most patients
had noticed any change in symptoms. Frequent home testing by a
finger-stick test has recently been shown to be feasible and might
be a useful monitoring strategy.20 However, natriuretic peptides
are influenced by other factors including renal function and heart
rhythm, which may make interpretation difficult when measured in
isolation.
Although echocardiography requires a good acoustic window
and an experienced operator, the increasing availability and low
cost of pocket-size ultrasound devices is likely to increase their use
by health professionals in the home and outpatient settings.21–23
The usefulness of these hand-held devices in identifying early signs
of deterioration, including IVC distension, the presence of lung
comets, or evidence of pleural effusion, has recently been reported
and is being assessed in several prospective clinical studies.
Measurements of bio-impedance using suitably enabled weighing
scales (e.g. the Tanita body composition analyser) can be used in
combination with predictive models to assess body composition
including total body water. However, this approach may have a
decreased sensitivity to detect changes in thoracic fluid because
the trunk accounts for a disproportionately small fraction of the
whole-body bio-impedance (5–12%) compared with body weight
(∼50%). This may limit the accuracy in certain clinical populations
where small changes in thoracic fluid play an important role. Early
stages of worsening HF are often characterized by an increase
in pulmonary pressures in the absence of weight gain, suggesting
that pulmonary volume overload might be predominantly due to
fluid redistribution rather than fluid retention.24,25 Our results
suggest that transthoracic bio-impedance can measure localized
volume overload in the absence of a substantial gain in weight.
Furthermore, haematocrit did not change, suggesting that no
substantial change in plasma volume had occurred.
Taken together, these data suggest the following sequence of
events. Medication omission, perhaps especially of diuretics, results
in net fluid retention, vasoconstriction, a rise in arterial and
ventricular filling pressures and, consequently, natriuretic peptides.
The rise in natriuretic peptides, blood pressure, and glomerular
filtration serves to limit, at least temporarily, the tendency to
overall salt and water retention. However, vulnerable vascular beds,
such as the lung, are still prone to an increase in tissue fluid prior
to developing overt oedema.
Although transthoracic bio-impedance is mainly determined by
fluid content in tissue, it is also affected by physical characteris-
tics, e.g. chest geometry. So far, there are no reliable normaliza-
tion techniques that enable the definition of an absolute cut-off to
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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discriminate between patients with and without congestion. How-
ever, serial measurements, as obtained daily through HTM, may
indicate deviations of transthoracic bio-impedance from a patient’s
personalized normal range.26 Novel sensors such as the BIM could
be easily incorporated into a HTM system tailored for patients with
HF.27,28
A recent alternative to bio-impedance is remote dielectric sens-
ing (ReDS) which measures lung fluid using low-power electromag-
netic radiation.29,30 However, this technique is unable to distinguish
between intravascular and parenchymal fluid, and thus may pre-
dominantly measure pulmonary venous distension.
Advances in technology have made it possible to create HTM
systems that can monitor symptoms, weight, heart rate and
rhythm, and blood pressure, as well as providing medication
reminders and educational material. Whether such systems can
reduce hospitalizations and/or improve prognosis is controversial,
although the most recent Cochrane analysis suggests that it does.31
The identification of a reliable and robust method for measuring,
recording, and reporting subclinical increases in congestion and its
likely cause might allow the development of personalized HTM
systems. A wide range of sensors are being used or considered
for integration into HTM systems, including bio-impedance mon-
itoring, acoustic cardiography or pulse wave characteristics, lung
congestion, and point-of-care biomarker devices. Which, if any,
will prove useful for routine clinical practice is uncertain, but early
detection and control of congestion could play a key role in improv-
ing outcome for patients with HF.32
This study was a small, exploratory study and therefore not pow-
ered to observe subtle differences between study days. However,
when the effects of an intervention or its withdrawal are substantial
and consistent, large trials are not required, as this analysis clearly
shows. Indeed, large studies may be misleading by identifying statis-
tically significant differences that are clinically irrelevant. The study
was not blinded and it is possible that patients, although they were
asked not to, changed their dietary behaviour. It is possible that
dietary salt and water intake was lower on diuretic-free days and
this prevented a significant increase in weight. Measuring urinary
sodium excretion would have resolved this, but to do this reliably
requires highly compliant patients, preferably studied during admis-
sion to a metabolic ward with a carefully measured diet. We did
not have the resources to do this.
Conclusions
Increasing plasma NT-proBNP and declining transthoracic
bio-impedance might be used to detect congestion, while changes
in blood pressure and renal function might indicate whether this
is due to omission of medications or progression of disease.
The utility of this physiological pattern for the early detection of
congestion and the reasons for congestion should be tested by
the next generation of HTM systems.
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